JP2012514009A5 - - Google Patents

Download PDF

Info

Publication number
JP2012514009A5
JP2012514009A5 JP2011543730A JP2011543730A JP2012514009A5 JP 2012514009 A5 JP2012514009 A5 JP 2012514009A5 JP 2011543730 A JP2011543730 A JP 2011543730A JP 2011543730 A JP2011543730 A JP 2011543730A JP 2012514009 A5 JP2012514009 A5 JP 2012514009A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
compound according
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011543730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514009A (ja
JP5502106B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/069852 external-priority patent/WO2010078449A2/en
Publication of JP2012514009A publication Critical patent/JP2012514009A/ja
Publication of JP2012514009A5 publication Critical patent/JP2012514009A5/ja
Application granted granted Critical
Publication of JP5502106B2 publication Critical patent/JP5502106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011543730A 2008-12-31 2009-12-30 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法 Active JP5502106B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14185308P 2008-12-31 2008-12-31
US61/141,853 2008-12-31
US16950909P 2009-04-15 2009-04-15
US61/169,509 2009-04-15
US23784209P 2009-08-28 2009-08-28
US61/237,842 2009-08-28
PCT/US2009/069852 WO2010078449A2 (en) 2008-12-31 2009-12-30 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014010049A Division JP5805802B2 (ja) 2008-12-31 2014-01-23 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2012514009A JP2012514009A (ja) 2012-06-21
JP2012514009A5 true JP2012514009A5 (https=) 2014-03-13
JP5502106B2 JP5502106B2 (ja) 2014-05-28

Family

ID=41650053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011543730A Active JP5502106B2 (ja) 2008-12-31 2009-12-30 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法
JP2014010049A Active JP5805802B2 (ja) 2008-12-31 2014-01-23 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014010049A Active JP5805802B2 (ja) 2008-12-31 2014-01-23 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法

Country Status (22)

Country Link
US (4) US8541448B2 (https=)
EP (3) EP3351248B1 (https=)
JP (2) JP5502106B2 (https=)
KR (5) KR101766619B1 (https=)
CN (2) CN102333759A (https=)
AU (1) AU2009334511C1 (https=)
BR (1) BRPI0923861B8 (https=)
CA (1) CA2748607A1 (https=)
CY (1) CY1120451T1 (https=)
DK (1) DK2384318T3 (https=)
ES (1) ES2657938T3 (https=)
HR (1) HRP20180289T1 (https=)
HU (1) HUE036405T2 (https=)
IL (3) IL213852A (https=)
LT (1) LT2384318T (https=)
MX (3) MX381407B (https=)
NO (1) NO2384318T3 (https=)
PL (1) PL2384318T3 (https=)
PT (1) PT2384318T (https=)
SI (1) SI2384318T1 (https=)
SM (1) SMT201800071T1 (https=)
WO (1) WO2010078449A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN102757390B (zh) * 2011-04-27 2015-04-22 中国中化股份有限公司 一种制备2-甲氧基-4-肼基-5-氟嘧啶的方法
US10376481B2 (en) * 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2880432C (en) * 2012-08-21 2023-03-14 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) * 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
HRP20191000T1 (hr) * 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
US9656972B2 (en) 2013-07-02 2017-05-23 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
AU2014305843B2 (en) * 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2015084158A1 (en) * 2013-12-06 2015-06-11 N.V. Nutricia A pyrimidine derivative and a fatty acid source for use in the treatment of constipation
RU2703456C2 (ru) * 2014-07-25 2019-10-17 Тайсо Фармасьютикал Ко., Лтд. Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом
RS61409B1 (sr) * 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
DE102014019388A1 (de) 2014-12-29 2016-06-30 Susanne Wagner Arzneimittel auf der Basis von Maghämit zur gleichzeitigen Reduzierung der gastrointestinalen Natriumresorption und Phosphatresorption
HK1246718A1 (zh) * 2015-01-07 2018-09-14 斯克利普斯研究所 用於治疗囊性纤维化的化合物
JP6421100B2 (ja) * 2015-09-04 2018-11-07 株式会社ダイセル カルボン酸アミド化合物の製造方法
US10016379B2 (en) * 2015-10-30 2018-07-10 Robin L. Webb Method of treatment for third spacing
CA3012700A1 (en) * 2016-02-01 2017-08-10 Arrakis Therapeutics, Inc. Compounds and methods of treating rna-mediated diseases
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
MX2019008171A (es) * 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
MX2020001412A (es) 2017-08-04 2020-08-03 Ardelyx Inc Compuestos y métodos para tratar la hiperpotasemia.
BR112020008676A2 (pt) 2017-11-02 2020-10-27 Ube Industries, Ltd. composto, e, composição farmacêutica.
WO2019091503A1 (en) 2017-11-13 2019-05-16 Zentiva K.S. Solid forms of tenapanor and method of preparation of tenapanor
WO2019109046A1 (en) 2017-11-30 2019-06-06 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
CN109897044A (zh) 2017-12-07 2019-06-18 北京大学 抗神经病理性疼痛化合物及其制备方法
WO2020051014A1 (en) 2018-09-04 2020-03-12 Teva Pharmaceuticals International Gmbh Processes for the preparation of tenapanor and intermediates thereof
CN109321529A (zh) * 2018-10-19 2019-02-12 浙江工商大学 一种体外肠道模型的构建方法和应用
PH12021551892A1 (en) 2019-02-07 2022-08-01 Ardelyx Inc Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020181555A1 (zh) * 2019-03-14 2020-09-17 深圳仁泰医药科技有限公司 Nhe3抑制剂的晶型a及其制备方法和应用
EA202192414A1 (ru) 2019-05-16 2022-03-02 Эли Лилли Энд Компани Соединения-ингибиторы натрий-водородного обменника 3
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
CN112679427B (zh) * 2019-10-17 2023-05-12 江苏恒瑞医药股份有限公司 四氢异喹啉类衍生物、其制备方法及其在医药上的应用
CN111217490B (zh) * 2019-12-30 2024-09-06 北京航天环境工程有限公司 一种轻型填料的双层生物滤池系统和应用
CA3190778A1 (en) * 2020-08-04 2022-02-10 Sigilon Therapeutics, Inc. Heteroaryl and heterocyclyl compounds
CN112047881B (zh) * 2020-10-10 2023-04-11 山东汇海医药化工有限公司 一种坦帕诺的制备方法
CN116963725A (zh) 2020-12-04 2023-10-27 阿德利克斯股份有限公司 特纳帕诺的口服制剂
CN114702478B (zh) * 2020-12-18 2024-01-05 上海济煜医药科技有限公司 苯并杂环取代四氢异喹啉类化合物
CN114805202A (zh) * 2021-01-28 2022-07-29 江西济民可信集团有限公司 苯磺酰胺类化合物及其制备方法和应用
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑hdac6抑制劑及其用途
US20250368618A1 (en) * 2022-06-20 2025-12-04 Shanghai Jeyou Pharmaceutical Co., Ltd. Benzoheterocyclic substituted tetrahydroisoquinoline compound salt form and preparation method therefor
CN116284240B (zh) * 2023-04-04 2026-04-14 江苏大学 一种仿生类肽防冰抗冻剂及其制备方法和应用

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926891A (en) 1974-03-13 1975-12-16 Dow Chemical Co Method for making a crosslinkable aqueous solution which is useful to form soft, water-swellable polyacrylate articles
US3935099A (en) 1974-04-03 1976-01-27 The United States Of America As Represented By The Secretary Of Agriculture Method of reducing water content of emulsions, suspensions, and dispersions with highly absorbent starch-containing polymeric compositions
US3997484A (en) 1974-04-03 1976-12-14 The United States Of America As Represented By The Secretary Of Agriculture Highly-absorbent starch-containing polymeric compositions
US4090013A (en) 1975-03-07 1978-05-16 National Starch And Chemical Corp. Absorbent composition of matter
JPS51125468A (en) 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
JPS5346389A (en) 1976-10-07 1978-04-25 Kao Corp Preparation of self-crosslinking polymer of acrylic alkali metal salt
US4190562A (en) 1977-04-04 1980-02-26 The B. F. Goodrich Company Improved water absorbent copolymers of copolymerizable carboxylic acids and acrylic or methacrylic esters
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4286082A (en) 1979-04-06 1981-08-25 Nippon Shokubai Kagaku Kogyo & Co., Ltd. Absorbent resin composition and process for producing same
JPS6025045B2 (ja) 1980-03-19 1985-06-15 製鉄化学工業株式会社 塩水吸収能のすぐれたアクリル酸重合体の製造方法
JPS57158209A (en) 1981-03-25 1982-09-30 Kao Corp Production of bead-form highly water-absorbing polymer
JPS5832607A (ja) 1981-08-20 1983-02-25 Kao Corp 吸水性に優れた吸水材料の製造法
US4985518A (en) 1981-10-26 1991-01-15 American Colloid Company Process for preparing water-absorbing resins
JPS6187702A (ja) 1984-10-05 1986-05-06 Seitetsu Kagaku Co Ltd 吸水性樹脂の製造方法
US4708997A (en) 1985-07-22 1987-11-24 The Dow Chemical Company Suspending agent for the suspension polymerization of water-soluble monomers
US4806532A (en) 1985-10-08 1989-02-21 Mayo Foundation For Medical Education And Research Inhibition of epithelial phosphate transport
DE3544770A1 (de) 1985-12-18 1987-06-19 Stockhausen Chem Fab Gmbh Verfahren und vorrichtung zum kontinuierlichen herstellen von polymerisaten und copolymerisaten der acrylsaeure und/oder methacrylsaeure
US4766004A (en) 1986-12-19 1988-08-23 Warner-Lambert Company Crunchy, highly palatable, bulk-increasing, dietary fiber supplement composition
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
US4999200A (en) 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
US5149541A (en) 1988-10-03 1992-09-22 The Procter & Gamble Company Psyllium-containing produces with a distribution of particle size
US5145906A (en) 1989-09-28 1992-09-08 Hoechst Celanese Corporation Super-absorbent polymer having improved absorbency properties
US5126150A (en) 1990-10-01 1992-06-30 The Procter & Gamble Company Compositions containing psyllium
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
WO1993013128A1 (en) 1991-12-30 1993-07-08 Neurex Corporation Methods of producing analgesia and enhancing opiate analgesia
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
DK0612723T3 (da) 1993-02-20 1998-03-30 Hoechst Ag Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
CA2114815C (en) 1993-02-24 2005-06-14 Mark Kevin Melius Absorbent composite
US5629377A (en) 1993-03-10 1997-05-13 The Dow Chemical Company Water absorbent resin particles of crosslinked carboxyl containing polymers and method of preparation
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US5489670A (en) 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5650222A (en) 1995-01-10 1997-07-22 The Procter & Gamble Company Absorbent foam materials for aqueous fluids made from high internal phase emulsions having very high water-to-oil ratios
DE19518796A1 (de) 1995-05-22 1996-11-28 Hoechst Ag Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP1336409B1 (en) 1995-06-27 2007-04-11 Eisai R&D Management Co., Ltd. Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US5550167A (en) 1995-08-30 1996-08-27 The Procter & Gamble Company Absorbent foams made from high internal phase emulsions useful for acquiring aqueous fluids
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
BR9611820A (pt) 1995-11-24 1999-07-13 Smithkline Beecham Spa Derivados de quinolina
DE19548812A1 (de) 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
EP0837055A1 (en) 1996-07-30 1998-04-22 Hoechst Aktiengesellschaft Substituted Indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them
DE19633966A1 (de) 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU4176997A (en) 1996-09-16 1998-04-02 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines
ES2302350T3 (es) 1997-02-28 2008-07-01 Nycomed Gmbh Combinacion sinergica de inhibidores de pde y agonistas de adenilatociclasa o agonistas de guanililciclasa.
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
KR100219918B1 (ko) 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
DE19849722A1 (de) 1998-10-28 2000-05-04 Aventis Pharma Gmbh Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2371910A1 (en) 1999-01-21 2000-07-27 Brian E. Peerce Inhibitors of intestinal apical membrane na/phosphate co-transportation
US6624150B2 (en) 1999-02-26 2003-09-23 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US6287609B1 (en) 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
HK1047091B (en) 1999-07-19 2008-07-04 University Of North Carolina At Chapel Hill Pharmacologically active compounds with two covalently linked active principles (sodium channel blocker/p2y2 receptor agonist) for the treatment of mucosal surfaces
AR030911A1 (es) 1999-07-20 2003-09-03 Smithkline Beecham Corp Uso de n-aril-2-sulfonamidobenzamidas para la manufactura de un medicamento para el tratamiento de la insuficiencia renal cronica y composiciones farmaceuticas
US6107356A (en) 1999-08-23 2000-08-22 The Procter & Gamble Company High suction polymeric foam materials
DE19941764A1 (de) * 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
DE19945302A1 (de) 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
ES2226933T3 (es) 1999-11-01 2005-04-01 John Rhodes Composicion para tratar el estreñimiento y el sindrome del intestino irritable.
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU3580001A (en) 2000-03-01 2001-09-12 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
DE10015248A1 (de) 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
WO2001082924A1 (en) 2000-05-02 2001-11-08 Smithkline Beecham Corporation Phosphate transport inhibitors
IL152587A0 (en) 2000-05-12 2003-05-29 Smithkline Beecham Corp Phosphate transport inhibitors
DE10043667A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
AU2002213048A1 (en) 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
AU2002232955A1 (en) 2000-11-20 2002-05-27 Dow Global Technologies Inc. In vivo use of water absorbent polymers
DE10063294A1 (de) 2000-12-19 2002-07-04 Aventis Pharma Gmbh Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2905585C (en) 2001-03-29 2020-02-18 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
US6736705B2 (en) 2001-04-27 2004-05-18 Hitachi Global Storage Technologies Polishing process for glass or ceramic disks used in disk drive data storage devices
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
JP2007131532A (ja) 2001-09-28 2007-05-31 Kirin Brewery Co Ltd 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
AU2002354410A1 (en) 2001-12-05 2003-06-17 Japan Tobacco Inc. Triazole compound and medicinal use thereof
EP1453810B1 (de) * 2001-12-05 2009-03-18 Sanofi-Aventis Deutschland GmbH Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
DE10161767A1 (de) 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10163992A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
CA2479350A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
ATE337326T1 (de) 2002-03-19 2006-09-15 Genzyme Corp Hemmer des phosphattransports
WO2003097051A2 (en) 2002-05-17 2003-11-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
US7014862B2 (en) 2002-05-20 2006-03-21 The Procter & Gamble Company Chewable compositions containing a gel-forming extract of psyllium
TWI245308B (en) 2002-09-13 2005-12-11 Getters Spa Non-evaporable getter compositions which can be reactivated at low temperature after exposure to reactive gases at a higher temperature
CN1254051C (zh) 2002-10-25 2006-04-26 华为技术有限公司 城域网传输设备中用户数据业务子速率传送方法
US6923466B2 (en) 2002-12-17 2005-08-02 James Tsai Collapsible handcart capable of extending the area of carrier by operating handle
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US7026303B2 (en) 2003-02-18 2006-04-11 The Procter & Gamble Company Compositions comprising a polysaccharide component and one or more coating layers
WO2004085448A2 (en) 2003-03-19 2004-10-07 Genzyme Corporation Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
EP1614676A4 (en) 2003-03-27 2009-03-25 Kirin Pharma Kk CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF
DE112004001165T5 (de) 2003-06-25 2006-05-04 Cmet Inc., Yokohama Durch aktinische Strahlung härtbare stereolithographische Harzzusammensetzung mit verbesserter Stabilität
WO2005020612A1 (en) 2003-08-20 2005-03-03 Musky Communications (Proprietary) Limited Telephonic communication
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
US20050095578A1 (en) 2003-10-31 2005-05-05 Koller Manfred R. Method and apparatus for cell permeabilization
WO2005054705A2 (en) 2003-11-26 2005-06-16 Brian Judd Apparatus for dampening impact vibration in manual tools
US20050244367A1 (en) 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
BRPI0511127A (pt) 2004-05-14 2007-11-27 Univ North Carolina prouroguanilina e análogos sintéticos ou produtos da clivagem proteolìtica dela derivados, como agentes terapêuticos e de diagnósticos para doenças que envolvem a homeostasia de sal e/ou de lìquidos
KR20070038042A (ko) 2004-05-14 2007-04-09 파세코 코퍼레이션 컨테이너 핸들러들을 위한 상황 보고 디바이스들을 만드는장치 및 방법
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
JP5301834B2 (ja) 2004-10-13 2013-09-25 ロリク アーゲー 光架橋性材料
DE102004054847A1 (de) 2004-11-13 2006-05-24 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
ATE476272T1 (de) 2005-08-29 2010-08-15 Demain Technology Pty Ltd Kraftbetriebenes werkzeug
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
CA2626961A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
US7694181B2 (en) 2005-12-12 2010-04-06 Archivas, Inc. Automated software testing framework
GB0610009D0 (en) 2006-05-19 2006-06-28 Health Prot Agency Culture medium
GB2438389A (en) 2006-05-23 2007-11-28 Gkn Aerospace Transparency Sys Heating system for leading edge of aircraft
US20120283411A9 (en) 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8617903B2 (en) 2007-01-29 2013-12-31 The Invention Science Fund I, Llc Methods for allergen detection
WO2008106429A2 (en) 2007-02-26 2008-09-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
EP2671584A3 (en) 2007-05-04 2014-03-26 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.

Similar Documents

Publication Publication Date Title
JP2012514009A5 (https=)
JP2011105738A5 (https=)
JP2009545527A5 (https=)
JP2012107057A5 (https=)
JP2009502793A5 (https=)
JP2007269812A5 (https=)
JP2013532687A5 (https=)
JP2009535462A5 (https=)
JP2010501534A5 (https=)
JP2017537066A5 (https=)
JP2014520248A5 (https=)
JP2011510079A5 (https=)
JP2013014622A5 (https=)
JP2011508438A5 (https=)
RU2582676C3 (ru) Некоторые химические соединения, композиции и способы
JP2010001302A5 (https=)
JP2016518337A5 (https=)
JP2011121989A5 (https=)
JO3757B1 (ar) التركيبات الصيدلانية التي تشمل على نيلوتينيب أو أملاحه
CL2014000663A1 (es) Compuestos derivados de 2-oxo-1,2,3,4-tetrahidroquinolina, inhibidores de aldosterona sitasa (cyp11b2 o cyp11b1); proceso para prepararlos; composicion farmaceutica;metodo de tratamiento o profilaxis; y uso para el tratamiento o la profilaxis de una enfermedad renal cronica o fallo cardiaco congestivo, entre otras.
JP2007522220A5 (https=)
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
JP2006298933A5 (https=)
JP2011527299A5 (https=)
JP2011519871A5 (https=)